Merck's MASH drug efinopegdutide clears liver disease in up to 63% of patients in a mid-stage trial
Merck's experimental drug efinopegdutide showed positive results in a Phase 2b trial for treating metabolic dysfunction-associated steatohepatitis (MASH), resolving the disease in up to 63% of patients after 52 weeks. The trial involved 381 adults with moderate or advanced fibrosis, with varying doses of the drug compared to placebo. Merck licensed the drug from Hanmi Pharmaceutical and it has received FDA Fast Track designation.
How this was made
The 30-second read
Why it matters
The trial results could accelerate Merck's pipeline valuation and influence MASH treatment market dynamics.
Market read
First disclosure of strong Phase 2b data for a MASH drug, likely to move Merck's stock and affect the broader metabolic disease sector.
What to watch
Potential competition from semaglutide and regulatory timelines may temper upside.
Background
Merck's efinopegdutide is a GLP‑1/glucagon dual agonist licensed from Hanmi, now Fast‑Tracked by the FDA.
Ticker impact
Merck reported Phase 2b trial data showing up to 63% MASH resolution, a first disclosure of pivotal clinical results.
likely upward pressure as market prices in strong efficacy data
Phase 2b data with high response rates and Fast Track designation suggest significant commercial potential.
Market effects
Strengthens the MASH/NAFLD therapeutic space, may pressure peers like Novo Nordisk.
U.S. biotech sector could see modest gains on the back of the data.
Highlights growing interest in metabolic disease treatments worldwide.
Counterpoint
If later-phase data falter or safety concerns emerge, the initial enthusiasm could reverse.
Key entities
- CompanyMerck
Pharmaceutical company reporting trial data.
- CompanyHanmi Pharmaceutical
Licensor of efinopegdutide.
